Karen Anthony

My research group studies how RNA (that bit between DNA and protein) is involved in neurological disease. This knowledge can be used to help develop new drugs. I have worked on pre-clinical and clinical trials to develop RNA-based gene therapy approaches for types of dementia and neuromuscular disorders.

Working with Professor Francesco Muntoni at University College London, my focus for the last seven years has been on developing exon skipping as a therapeutic strategy for for Duchenne muscular dystrophy (DMD). This work led to the first FDA-approved drug for DMD (called eteplirsen, or exondys 51). Being one of the first to see evidence down the microscope that an experimental drug is working remains a defining and motivational moment for me.

I maintain strong collaborative links to The Dubowitz Neuromuscular Centre at University College London and The Maurice Wohl Clinical Neuroscience Institute at King’s College London.

My full academic biography and publication record can be found on my institutional webpage: http://www.northampton.ac.uk/d... and on ResearchGate: https://www.researchgate.net/p...

Follow me on Twitter: @Weekademia

January 2017